Indonesia and Russia are advancing discussions on a potential partnership to transfer pharmaceutical technology, aiming to bolster Indonesia’s domestic medicine production and reduce its dependence on imports. The collaboration seeks to enhance regulatory oversight of medicinal and food products, and expand access to essential healthcare treatments.
The talks involved Indonesia’s Food and Drug Authority (BPOM), headed by Taruna Ikrar, and Russian Deputy Minister of Industry and Trade Alexey Vladimirovich Gruzdev. They focused on several areas including pharmaceutical manufacturing, quality inspections, and the use of digital technologies to ensure product safety and traceability. Indonesia emphasized the need to increase local production of diabetes medications, such as insulin and glucagon-like peptide-1 (GLP-1) medicines, among other critical healthcare products.
Russia showed interest in transferring technology and possibly setting up manufacturing facilities in Indonesia for insulin, oncology medicines, and biotechnology products. Russian companies have already begun the process, with several having submitted product registration documents to BPOM. Both countries are working towards finalizing a memorandum of understanding to establish a framework for deeper collaboration.
The discussions also covered mutual recognition of Good Manufacturing Practice (GMP) certificates to streamline regulatory procedures and facilitate pharmaceutical market access in both nations. This proposal, however, requires further deliberation to ensure compatibility between the regulatory systems of the two countries.
To enhance Indonesia’s inspection capabilities, Russia offered technical training, including virtual reality-based simulations to prepare inspectors for pharmaceutical manufacturing assessments. The dialogue extended to digital regulatory systems and supply-chain monitoring, with both parties expressing a strong interest in continuing negotiations and exploring further cooperation through additional meetings and visits to pharmaceutical manufacturing sites.